Infinity Pharmaceuticals, Inc. News Releases http://investors.infi.com/ Infinity Pharmaceuticals, Inc. News Releases en Infinity Pharmaceuticals To Present At The 2019 BIO International Convention http://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-present-2019-bio-international CAMBRIDGE, Mass. , May 29, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that members of the management team will be participating in the 2019 BIO International Convention at Pennsylvania Convention Center , Philadelphia, PA. Wed, 29 May 2019 08:32:00 -0400 Infinity Pharmaceuticals, Inc. News Releases 16446 Infinity Pharmaceuticals To Present At B. Riley FBR Institutional Investor Conference http://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-present-b-riley-fbr-institutional CAMBRIDGE, Mass. , May 16, 2019 /PRNewswire/ --  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins , Infinity Pharmaceutical's Chief Executive Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019 , at 2:00 p.m. Thu, 16 May 2019 08:32:00 -0400 Infinity Pharmaceuticals, Inc. News Releases 16436 Infinity Pharmaceuticals Provides Company Update and First Quarter 2019 Financial Results http://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-provides-company-update-and-first-0 -- MARIO-275 Phase 2 Study in I/O Naïve Urothelial Cancer Patients on Track to Initiate in 2Q19 -- -- MARIO-3 Phase 2 Study in Front-Line Triple Negative Breast Cancer and Renal Cell Cancer Patients on Track to Initiate in 3Q19 -- -- Infinity Received Net Proceeds of $22.9M in Non-Dilutive Capital Tue, 07 May 2019 16:05:00 -0400 Infinity Pharmaceuticals, Inc. News Releases 16421 Infinity Announces the Date of Its First Quarter 2019 Financial Results Conference Call and Webcast http://investors.infi.com/news-releases/news-release-details/infinity-announces-date-its-first-quarter-2019-financial-results CAMBRIDGE, Mass. , April 30, 2019 /PRNewswire/ --  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, May 7 , at 4:30 p.m. ET to review its first quarter 2019 financial results and provide an update on the company. A live webcast of the conference call can be Tue, 30 Apr 2019 08:32:00 -0400 Infinity Pharmaceuticals, Inc. News Releases 16401 Infinity Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference http://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-present-18th-annual-needham-healthcare CAMBRIDGE, Mass. , April 2, 2019 /PRNewswire/ --  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins , Infinity Pharmaceutical's Chief Executive Officer, will present at the 18 th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 , at 3:30 p.m. Tue, 02 Apr 2019 08:32:00 -0400 Infinity Pharmaceuticals, Inc. News Releases 16366 Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update http://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-reports-full-year-2018-financial -- Copiktra™ Royalty Monetization for $30M in Gross Proceeds -- -- Roche/Genentech Clinical Collaboration on MARIO-3 in Front-Line Triple Negative Breast Cancer and Renal Cell Cancer -- -- BMS Clinical Collaboration on MARIO-275, a Randomized Study of IPI-549 and Opdivo® (nivolumab) in I/O Naïve Thu, 14 Mar 2019 07:32:00 -0400 Infinity Pharmaceuticals, Inc. News Releases 16351 Infinity To Initiate MARIO-3, A Phase 2 Multi-Arm Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer http://investors.infi.com/news-releases/news-release-details/infinity-initiate-mario-3-phase-2-multi-arm-study-evaluating-ipi - Infinity Enters into Master Clinical Supply Agreement with Roche to Provide atezolizumab (Tecentriq®) for MARIO-3 - - MARIO-3 Will Evaluate IPI-549 with Tecentriq and Abraxane® in Front-Line Triple Negative Breast Cancer and IPI-549 with Tecentriq and Avastin® in Front-Line Renal Cell Cancer - Thu, 14 Mar 2019 07:02:00 -0400 Infinity Pharmaceuticals, Inc. News Releases 16341 Infinity Announces the Date of Its Full Year 2018 Financial Results Conference Call and Webcast http://investors.infi.com/news-releases/news-release-details/infinity-announces-date-its-full-year-2018-financial-results CAMBRIDGE, Mass. , March 7, 2019 /PRNewswire/ --  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, March 14, 2019 , at 8:00 a.m. ET to review its full year 2018 financial results and provide an update on the company. Thu, 07 Mar 2019 16:05:00 -0500 Infinity Pharmaceuticals, Inc. News Releases 16331 Infinity Pharmaceuticals Announces Royalty Monetization of COPIKTRA™ for $30 Million Gross Proceeds http://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-announces-royalty-monetization - Infinity Retains $22.5 Million in Gross Proceeds After Sharing with Takeda - CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ --  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today a royalty monetization with HealthCare Royalty Partners (HCR) for the right to receive certain royalty Wed, 06 Mar 2019 07:32:00 -0500 Infinity Pharmaceuticals, Inc. News Releases 16321 Infinity Pharmaceuticals To Present At BIO CEO & Investor Conference http://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-present-bio-ceo-investor-conference CAMBRIDGE, Mass. , Feb. 4, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins , Infinity Pharmaceutical's Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019 , at 10:00 a.m. Mon, 04 Feb 2019 08:32:00 -0500 Infinity Pharmaceuticals, Inc. News Releases 16296